The MiddleEast Tapentadol market, by Therapeutic Application (Pain Management(Neuropathic Pain, Cancer Pain, and Others), and Cough Treatment), and byCountries (KSA, UAE, Bahrain, Oman, Qatar, Israel, Iran) was valued at US$ 0.86million in 2016 and is projected to exhibit a CAGR of 6.1% over the forecastperiod (2017–2025).
Rising prevalence ofpain-associated diseases such as cancer and diabetic neuropathy andunavailability of effective alternate therapy for management of neuropathicpain are expected to be the major factors driving growth of the Middle Easttapentadol market over the forecast period. Janssen Pharmaceutical sold itslicense of marketing and distribution of the U.S. to Depomed, Inc. and in April2017, Depomed, Inc. won the patent for tapentadol. Three ongoing clinicaltrials for tapentadol are being carried on for various indications and agegroups.
Tapentadol is an opioidanalgesic, indicated for severe pain management, on a daily or around the clockneed for treatment and long-term opioid treatment, for which alternativetreatment options are inadequate. Tapentadol is also indicated for neuropathicpain associated with diabetic peripheral neuropathy. It is widely used formanagement of acute, chronic, and cancer related pain among patients and isavailable legally on prescription. Nucynta ER is the first and onlyFDA-approved long-acting opioid analgesic designed to control both, nociceptivepain and neuropathic pain associated with diabetic peripheral neuropathy.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/1054
Nucynta is available as Palexiaoutside the U.S. territory. Nucynta ER is contraindicated for patientssuffering from significant respiratory depression, known or suspectedgastrointestinal obstruction, acute or severe bronchial asthma or hypercarbia,including paralytic ileus, concurrent use of monoamine oxidase inhibitors(MAOIs), and Hypersensitivity (e.g. anaphylaxis, angioedema) to tapentadol orto any other ingredients of the product or use of MAOIs within a period of 14days.
Positive results from thesetrials is expected to cause the tapentadol market to gain rapid traction.Currently, tapentadol is only approved for consumption by adults and is notrecommended for children due to its high therapeutic efficacy. However, one inthree clinical trials are subjected to pediatric use. Grünenthal GmbH is carrying out an open-labeltrial, enrolling subjects aged 6 years to 18 years, which is estimated to becompleted in December 2018. Another trial by St. Olavs Hospital is for pre- andpost-operative pain relief after primary knee arthroplasty with estimated studycompletion year 2021.
Browse 10 Market Data Tables And11 Figures Spread Through 106 Pages and In-depth TOC on Middle East TapentadolMarket, By Therapeutic Application (Pain Management (Neuropathic Pain, CancerPain, And Others), And Cough Treatment), and By Countries (KSA, UAE, Bahrain,Oman, Qatar, Israel, Iran) - Forecast To 2025.
Tapentadol can be used forvarious other applications, as it is also found to be the safest and bestfirst-line treatment choice for advanced chronic kidney disease. However, clinicaltrials are still required for it to be prescribed for the same. Furthermore,pilot studies have been performed on patients suffering from moderate-to-severechronic back pain, published in the National Center for BiotechnologyInformation. Increasing off-label applications for this moderately addictivedrug along with low competition for existing indications, and robust pipelineis expected to boost growth of the tapentadol market over the forecast period.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/tapentadol-market-1054
Key Takeaways of the Middle EastTapentadol Market:
The Middle East tapentadol marketis expected to exhibit a CAGR of 1% over the forecast period (2017–2025), owingto the high prevalence of pain-related diseases in countries such as Iran,Palestine, and Kingdom of Saudi Arabia. For instance, according to Journal ofTaibah University Medical Sciences, the prevalence of diabetic neuropathic painin Iran was 51.90% in 2016.
Positive results of clinicaltrials of tapentadol are expected to drive growth of the tapentadol marketfurther
Absence of generic drugs afterpatent win by Depomed, Inc. in 2016, has abolished the competition
Less likelihood of toughcompetition from any other opioid for neuropathic pain and absence of any otheropioid therapy under research is expected to support growth of the market
Some major players operating inthe tapentadol market are Depomed, Inc., Janssen Pharmaceutical, Inc.,Grünenthal, and Allergan, Plc.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/1054
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN: +050-5539-1737
